First-in-human safety and pharmacokinetic evaluation of seralutinib, an investigational inhaled tyrosine-protein kinase inhibitor for pulmonary hypertension
Pulmonary Pharmacology & Therapeutics · 2026-12 · 95 · 102453
DOI: 10.1016/j.pupt.2026.102453 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pulmonary Pharmacology & Therapeutics, 2026-12. Verfasst von Jianke Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gossamer Bio, Inc., San Diego, CA, USA. Electronic address: jli@gossamerbio.com. Die Arbeit nennt 16 Literaturangaben. Gefördert von: National Institutes of Health.
Abstract (Originalsprache)
OBJECTIVE: First-in-human studies were conducted to evaluate the safety, tolerability, and pharmacokinetics (PK) of single and multiple doses of inhaled seralutinib in healthy participants. METHODS: Two phase I, randomized, double-blind, placebo-controlled studies were conducted. In Study 1, participants received single ascending doses of seralutinib (3.75-48 mg) or placebo (Part 1) and multiple ascending doses of seralutinib (18 mg BID, 24 mg TID, and 48 mg TID) or placebo for 7 days (Part 2). In Study 2, participants received a single dose of seralutinib 90 mg or placebo (Part 1) and multiple doses of seralutinib (90 mg BID) or placebo for 7 days (Part 2). Sentinel dosing strategy was utilized for all cohorts. Safety was assessed. Seralutinib PK was characterized. RESULTS: 82 healthy participants completed the studies (20 received placebo; 37, single doses of seralutinib; 25, multiple doses of seralutinib BID or TID for 7 days). No serious adverse events (AEs) or AEs leading to withdrawal were reported. Most AEs were mild in severity. Following single and multiple dose inhalations, seralutinib was quickly absorbed (median tmax 5 min) into, and rapidly cleared from the systemic circulation. Mean terminal elimination half-life was 3.08-5.75 h. Seralutinib exposures increased in an approximately dose-proportional manner. Steady-state plasma levels were reached by Day 3 (multiple doses). Minimal accumulation in plasma was observed after multiple days of BID or TID doses. CONCLUSION: Consistent with its PK profile, seralutinib administered as single or multiple doses was generally well tolerated, with a favorable safety profile in healthy adults.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gossamer Bio, Inc., San Diego, CA, USA. Electronic address: jli@gossamerbio.com.
- Gossamer Bio, Inc., San Diego, CA, USA. Electronic address: lzisman@gossamerbio.com.
- Gossamer Bio, Inc., San Diego, CA, USA. Electronic address: mcravets@gossamerbio.com.
- Gossamer Bio, Inc., San Diego, CA, USA. Electronic address: raranda@gossamerbio.com.
Förderung
- National Institutes of Health
Zitieren
APA
Li, J., Zisman, L. S., Cravets, M., & Aranda, R. (2026). First-in-human safety and pharmacokinetic evaluation of seralutinib, an investigational inhaled tyrosine-protein kinase inhibitor for pulmonary hypertension. Pulmonary Pharmacology & Therapeutics, 95, 102453. https://doi.org/10.1016/j.pupt.2026.102453
Vancouver
Li J, Zisman LS, Cravets M, Aranda R. First-in-human safety and pharmacokinetic evaluation of seralutinib, an investigational inhaled tyrosine-protein kinase inhibitor for pulmonary hypertension. Pulmonary Pharmacology & Therapeutics. 2026;95:102453. doi:10.1016/j.pupt.2026.102453
BibTeX
@article{Li2026,
author = {Li, Jianke and Zisman, Lawrence S and Cravets, Matt and Aranda, Richard},
title = {First-in-human safety and pharmacokinetic evaluation of seralutinib, an investigational inhaled tyrosine-protein kinase inhibitor for pulmonary hypertension},
journal = {Pulmonary Pharmacology & Therapeutics},
year = {2026},
volume = {95},
pages = {102453},
doi = {10.1016/j.pupt.2026.102453}
}
EUVIMED